From: Impact of comorbidities in COPD clinical control criteria. The CLAVE study
Univariate analysis | Multivariate analysisa; OR (CI 95%); p-value | ||||
---|---|---|---|---|---|
Total | Controlled | Non-controlled | p | ||
Asthma | 192 (4.0) | 49 (3.7) | 143 (4.1) | 0.5235 | 1.23 (0.88–1.72); p = 0.2185 |
Sleep disturbance (OAHAS or equivalent) | 715 (14.9) | 151 (11.4) | 564 (16.2) | < 0.0001 | 1.57 (1.29–1.91); p < 0.0001 |
Lung neoplasm | 125 (2.6) | 32 (2.4) | 93 (2.7) | 0.6234 | 1.08 (0.72–1.63); p = 0.7109 |
Sinus node disease | 37 (0.8) | 8 (0.6) | 29 (0.8) | 0.4188 | 1.24 (0.56–2.73); p = 0.6001 |
Arterial hypertension | 2457 (51.2) | 624 (47.2) | 1833 (52.7) | 0.0007 | 1.20 (1.05–1.37); p = 0.0076 |
Chronic atrial fibrillation | 553 (11.5) | 106 (8.0) | 447 (12.8) | < 0.0001 | 1.56 (1.25–1.96); p = 0.0001 |
Atrio-ventricular block | 50 (1.0) | 11 (0.8) | 39 (1.1) | 0.3784 | 1.24 (0.63–2.43); p = 0.5408 |
Thromboembolic disease (PTE or DVT precedents) | 106 (2.2) | 26 (2.0) | 80 (2.3) | 0.4833 | 1.18 (0.75–1.85); p = 0.4836 |
Iron-deficiency anemia (Hgb < 13 g/l) | 193 (4.0) | 41 (3.1) | 152 (4.4) | 0.0458 | 1.30 (0.91–1.85); p = 0.1512 |
Other anemia (Hgb13 g/l) | 154 (3.2) | 27 (2.0) | 127 (3.7) | 0.0047 | 1.69 (1.11–2.59); p = 0.0152 |
Dyslipidemia | 1726 (36.0) | 460 (34.8) | 1266 (36.4) | 0.3039 | 1.08 (0.94–1.24); p = 0.2664 |
Abdominal obesity (men > 102 cm; women 88 cm) | 757 (15.8) | 173 (13.1) | 584 (16.8) | 0.0017 | 1.42 (1.18–1.71); p = 0.0002 |
Osteoporosis | 376 (7.8) | 73 (5.5) | 303 (8.7) | 0.0002 | 1.58 (1.21–2.06); p = 0.0008 |
Anxiety | 677 (14.1) | 114 (8.6) | 563 (16.2) | < 0.0001 | 2.06 (1.66–2.55); p < 0.0001 |
Depression | 567 (11.8) | 89 (6.7) | 478 (13.7) | < 0.0001 | 2.21 (1.74–2.80); p < 0.0001 |
Gastroesophageal reflux | 372 (7.7) | 71 (5.4) | 301 (8.7) | 0.0001 | 1.72 (1.32–2.25); p < 0.0001 |
Digestive malignancy | 55 (1.1) | 16 (1.2) | 39 (1.1) | 0.7951 | 0.87 (0.48–1.57); p = 0.6405 |